FenofibrateThird Party Manufacturing in India

Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that regulates lipid metabolism. Upon activation, PPAR-alpha increases the expression of genes involved in fatty acid oxidation, lipoprotein lipase activity, and apolipoprotein A-I and A-II production. This leads to enhanced clearance of triglyceride-rich lipoproteins and increased production of high-density lipoprotein (HDL) cholesterol.

Fenofibrate is a prodrug that is rapidly hydrolyzed by tissue and plasma esterases to its active metabolite, fenofibric acid. The active form circulates bound to albumin and enters target cells where it binds to PPAR-alpha in the nucleus. This binding alters transcription of multiple genes involved in lipid and glucose homeostasis. The net effect is a significant reduction in serum triglycerides, moderate reduction in low-density lipoprotein (LDL) cholesterol, and an increase in HDL cholesterol.

Beyond its lipid-lowering effects, fenofibrate also exhibits anti-inflammatory properties by reducing the expression of vascular cell adhesion molecules and inflammatory cytokines. This pleiotropic effect contributes to its cardiovascular benefits. Fenofibrate is excreted primarily through the kidneys as glucuronide conjugates, with dose adjustments necessary in moderate to severe renal impairment.

Therapeutic Uses

Fenofibrate is prescribed for the treatment of:

• Hypertriglyceridemia: Fenofibrate is highly effective in reducing elevated triglyceride levels, often achieving 30-50% reduction depending on baseline severity.
• Mixed Dyslipidemia: For patients with elevated triglycerides and LDL cholesterol with low HDL, fenofibrate improves the entire lipid profile.
• Type IIa and IIb Hyperlipoproteinemia: Fenofibrate is indicated as adjunctive therapy to diet for patients with Fredrickson classification Type IIa (elevated LDL) and Type IIb (elevated LDL and VLDL) hyperlipoproteinemia.
• Prevention of Cardiovascular Events: In patients with metabolic syndrome or type 2 diabetes, fenofibrate reduces the risk of coronary heart disease events, particularly non-fatal myocardial infarction.
• Diabetic Dyslipidemia: Fenofibrate is particularly useful in type 2 diabetes patients who typically present with high triglycerides and low HDL.

Why Manufacturers Choose Fenofibrate

Fenofibrate remains one of the most widely prescribed lipid-lowering agents in India and globally, with consistent demand driven by the growing prevalence of metabolic syndrome, obesity, and type 2 diabetes. Indian contract manufacturers have developed robust capabilities for fenofibrate production across multiple strengths, with both standard and micronized formulations available. The molecule is well-suited for third party manufacturing in India due to its established supply chain, well-characterized API synthesis, and high-volume consumption. Fenofibrate also offers excellent export potential to price-sensitive markets in Asia, Africa, and Latin America. PCD franchise companies consistently include fenofibrate in their cardiovascular portfolios, making it a staple molecule for contract manufacturing partnerships.